Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors. Progress in immune-based strategies has opened new therapeutic avenues using a number of techniques destined to eliminate malignant cells. In the present review, we overview current knowledge on the importance, successes and difficulties of immunotherapy in liver tumors, including preclinical data available in animal models and information from clinical trials carried out during the lasts years. This review shows that new options for the treatment of advanced liver tumors are urgently needed and that there is a ground for future advances in the field
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver, with poor pr...
金沢大学がん進展制御研究所Tumor immunity proceeds through multiple processes, which consist of antigen presentati...
The possibility of using the immune system of patients to control tumor outgrowth in a therapeutic s...
Increasing evidence suggests that immune responses are involved in the control of cancer and that th...
In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach fo...
Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is s...
Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment...
One of the most important abilities of a tumor is to establish a state of immunosuppression inside t...
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surge...
Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflame...
Cancer is a major disease threatening human health. The overall prognosis for hepatocellular carcino...
Hepatocellular carcinoma (HCC) carries an unfavorable prognosis and novel therapeutic strategies are...
International audienceHepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor ...
In the latest years, antineoplastic immunotherapy revolutionised the therapeutic landscape in oncolo...
SummaryCurrent systemic treatment options for patients with hepatocellular carcinoma (HCC) are limit...
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver, with poor pr...
金沢大学がん進展制御研究所Tumor immunity proceeds through multiple processes, which consist of antigen presentati...
The possibility of using the immune system of patients to control tumor outgrowth in a therapeutic s...
Increasing evidence suggests that immune responses are involved in the control of cancer and that th...
In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach fo...
Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is s...
Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment...
One of the most important abilities of a tumor is to establish a state of immunosuppression inside t...
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surge...
Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflame...
Cancer is a major disease threatening human health. The overall prognosis for hepatocellular carcino...
Hepatocellular carcinoma (HCC) carries an unfavorable prognosis and novel therapeutic strategies are...
International audienceHepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor ...
In the latest years, antineoplastic immunotherapy revolutionised the therapeutic landscape in oncolo...
SummaryCurrent systemic treatment options for patients with hepatocellular carcinoma (HCC) are limit...
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver, with poor pr...
金沢大学がん進展制御研究所Tumor immunity proceeds through multiple processes, which consist of antigen presentati...
The possibility of using the immune system of patients to control tumor outgrowth in a therapeutic s...